ME-344

N/A

Report date: 2025/11/21 10:02:57
NME

Base Information

Drug NameME-344
Drug Alias NameME-344NV-344WE-868
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomSpain
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMei Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCentro Nacional De Investigaciones OncológicasMei Pharma IncAardvark Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursColorectal NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A